EA Pharma Co., Ltd
EA Pharma Co., Ltd., headquartered in Japan, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of innovative gastrointestinal treatments. Founded in 2015, the company has quickly established itself as a leader in its field, focusing on prescription medications that address unmet medical needs. With a strong operational presence in Asia and beyond, EA Pharma is dedicated to enhancing patient outcomes through its unique product offerings, which include advanced formulations and targeted therapies. The company’s commitment to research and development has led to significant milestones, positioning it as a trusted name in the healthcare sector. EA Pharma's dedication to quality and innovation continues to drive its success and reputation in the competitive pharmaceutical landscape.
DitchCarbon Score
How does EA Pharma Co., Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
EA Pharma Co., Ltd's score of 21 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
EA Pharma Co., Ltd, headquartered in Japan, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. However, the company is part of a corporate family relationship with Eisai Co., Ltd., from which it inherits climate commitments and initiatives. As a current subsidiary of Eisai Co., Ltd., EA Pharma aligns with the sustainability goals set by its parent company. Eisai has established various climate initiatives, including targets under the Science Based Targets initiative (SBTi), participation in the Carbon Disclosure Project (CDP), and commitments to the RE100 initiative, which aims for 100% renewable energy usage. These initiatives reflect a broader commitment to reducing carbon emissions and enhancing sustainability practices within the pharmaceutical industry. While specific reduction targets for EA Pharma are not detailed, the company's affiliation with Eisai suggests a commitment to industry-standard climate action and emissions reduction strategies. As the company continues to develop its sustainability framework, it is expected to adopt similar ambitious targets in line with its parent company's efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 49,457,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 55,830,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 456,386,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
EA Pharma Co., Ltd is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
